Mobile

A trial investigating the safety and efficacy of a drug combination Ledipasvir/Sofosbuvir for Subjects with hepatitis C who are on dialysis for kidney disease

Update Il y a 4 ans
Reference: EUCTR2016-003489-25

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

 To evaluate the antiviral efficacy of treatment with LDV/SOF for 8,12, or 24 weeks in subjects with chronic hepatitis C virus (HCV) infection who are on dialysis for ESRD, as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12)  To evaluate the safety and tolerability of each treatment regimen

Inclusion criteria

  • Chronic hepatitis C virus infection

Links